drugset / Trial / NCT01161524

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524

Phase 2 Completed 133 enrolled Eisai Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to investigate the short- and long-term effects of perampanel on cognition, growth, and development in adolescents.

Timeline

Start
2010-09
Primary completion
2013-06
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 8 mg
Subject Perampanel Small molecule 12 mg

Indications